drugset / Trial / NCT03544099
Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA
Phase 2
Terminated
2 enrolled
National Health Research Institutes, Taiwan
Chang Gung Memorial Hospital · collabChanghua Christian Hospital · collabChina Medical University Hospital · collabKoo Foundation Sun Yat-Sen Cancer Center · collabNational Cheng-Kung University Hospital · collabNational Taiwan University Hospital · collabTaichung Veterans General Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, multi-center, open-label, phase II trial to examine the efficacy of pembrolizumab for prolonging the one-year disease free survival in nasopharyngeal carcinoma patients with solely detectable EBV DNA after curative chemoradiation. Sixty-three patients will be enrolled in the trial.
Timeline
- Start
- 2019-05-07
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
Outcome
Outcome not reported
Stopped (Enrollment): “Difficult to recruit Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |